To all BNMS Members,
We want to thank you for your continued support.
Your membership has allowed us to achieve so much this year
In 2017 the BNMS has:
The 2017 round of the BNMS Workforce Survey has now been launched.
It is very important that the survey is completed by as many Nuclear Medicine/Radiopharmacy departments as possible, so that the growing pressures to deliver more output but with less resources can be monitored in a consistent way.
View the President's Letter here
Last year we had a great response rate of over 50%, we hope to increase this even more this year!
To help us make this run as smoothly as possible, please keep us informed of any changes to your departmental contacts or if you think your department hasn't been contacted by emailing Caroline Oxley at email@example.com
Clinicians' Guides to Radionuclide Hybrid Imaging PET/CT
I. Kayani (Ed.)
PET/CT in Hodgkin’s Lymphoma
M. Hofman, R. Hicks (Eds.)
PET/CT in Melanoma
G. Cook (Ed.)
PET/CT in Prostate Cancer
PET/CT in Cancer of Unknown Primary
W.L. Wong (Ed.)
PET/CT in Head and Neck Cancer
N. Purandare, S. Shah (Eds.)
PET/CT in Hepatobiliary and Pancreatic Malignancies
Press Statement on Euratom and supply of medical isotopes following Brexit from the British Nuclear Medicine Society, supported by the Royal College of Radiologists and Royal College of Physicians
On Wednesday 12 July there was a parliamentary debate on the implications for the UK on withdrawing from the Euratom Treaty. Since 1957 the Euratom framework has enshrined the regulation and safeguards for the transportation and use of radioactive materials and governs UK international nuclear cooperation agreements with European and third party countries, including Canada, Japan and the USA. Withdrawing from Euratom will affect the arrangements for the supply and use of radioactive isotopes to industry, power generation, academia and medicine.
Below are links to various articles relating to how Brexit will impact on Nuclear Medicine.